TXNRD1 and cancer: Therefore, similarly to the GPXs, it is likely that the high metabolic demand and increased oxidative stress results in cancer cells upregulating TXNRD1 to combat elevated ROS, deeming TXNRD1 an appropriate target for therapeutic development.